Earnings Ahead

SRPT - Sarepta Therapeutics Inc.

106.4 -1.88 -1.74

Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc.

About

Profile

Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.


Headquarters

Cambridge, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

SRPT

Shares tumbled 18% after posting a steep loss in the first-quarter, and slashing its full-year net product revenue forecast to a range of $2.30 billion to $2.60 billion. Analysts were looking for that metric to be between $2.90 billion and $3.10 billion.


 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M
  • Sarepta Therapeutics Q3 2023 Earnings Preview
  • Biggest stock movers today: Caterpillar, Arista Networks, BP, Pinterest and more
  • Sarepta in selloff after late-stage setback for Duchenne candidate
  • 5 stocks to watch on Tuesday: Sarepta Therapeutics, Pfizer, AMD and more
  • Sarepta Phase 3 study for DMD drug fails to meet primary endpoint
  • Mizuho doesn't see Sarepta price decline connected to EMBARK study
  • Sarepta Therapeutics Non-GAAP EPS of -$0.85 beats by $0.15, revenue of $261.2M beats by $5.36M
  • Sarepta Therapeutics Q2 2023 Earnings Preview
  • Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023
  • Catalyst Watch: CPI, major bank earnings, Amazon Prime Day and CAVA ratings
  • Sarepta raises $102M from selling priority review voucher
  • Sarepta down 9% as Duchenne treatment gets narrow population approval
  • Sarepta Duchenne treatment wins FDA nod, but with smaller population (update)
  • Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy
  • Catalyst watch: C3.ai and Salesforce earnings, Knife River debut, Kenvue ratings & Faraday Future event
  • Hot Stocks: ANF, URBN and PANW rise on earnings; A, XPEV fall on weak outlooks; OCGN slides
  • Sarepta says FDA needs more time to review muscular dystrophy drug
  • Billions of dollars at stake as FDA shortcut allows half-proven drugs - report
  • Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

Earnings History

Date EPS / Forecast Revenue / Forecast
October 27, 2021 - / -1.83 - / 171.36M
August 4, 2021 -1.02 / -1.3 164.09M / 167.07M
May 5, 2021 -2.1 / -1.83 146.93M / 145.81M Beat!
March 1, 2021 -2.4 / -1.8 145.14M / 150.38M
November 5, 2020 -2.5 / -1.71 143.92M / 137.76M Beat!
August 5, 2020 -1.93 / -1.72 137.36M / 116.29M Beat!
May 6, 2020 -0.23 / -1.92 113.67M / 116.49M
February 26, 2020 -3.16 / -1.81 100.11M / 98.8M Beat!
November 7, 2019 -1.7 / -1.35 99.04M / 98.48M Beat!
August 7, 2019 -3.74 / -1.07 94.67M / 91.05M Beat!
May 8, 2019 -1.07 / -1.61 87.01M / 86.6M Beat!
February 27, 2019 -2.05 / -1.02 84.42M / 84.92M
October 24, 2018 -1.15 / -0.78 78.49M / 78.75M
August 8, 2018 -1.67 / -0.84 73.53M / 71.4M Beat!
May 3, 2018 -0.55 / -0.32 64.6M / 65.09M
February 26, 2018 - / -0.32 - / 55.57M
October 25, 2017 -0.76 / -0.85 45.95M / 40.77M Beat!
July 19, 2017 -0.46 / -0.77 35.01M / 22.38M Beat!
April 27, 2017 -0.71 / -0.81 16.34M / - Beat!
February 28, 2017 -0.71 / -0.45 5.42M / 46.83M
October 27, 2016 -1.18 / -0.52 - / 3.08M
Date Price Open High Low Vol Change
Jun 17 21.56 21.16
22.98
20.51
14.5M 2.96%
Jun 16 20.94 21.26
21.55
18.3
44.2M -42.12%
Jun 13 36.18 37.05
38.09
35.77
3.2M -3.03%
Jun 12 37.31 37.6
37.84
36.8
3.2M -1.32%
Jun 11 37.81 39.31
39.64
37.76
2.4M -3.22%
 
Jun 10 39.07 40
40.9
38.95
3.4M -1.61%
Jun 9 39.71 43.79
43.92
39.41
5.6M -7.67%
Jun 6 43.01 40.45
43.54
40.45
4.9M 9.69%
Jun 5 39.21 39.54
40.49
37.91
2.9M -0.83%
Jun 4 39.54 39.05
40.28
38.63
2.3M 1.72%
Jun 3 38.87 37.72
39.12
37.15
2.2M 2.99%
Jun 2 37.74 37.85
39.01
37.07
2.2M 0.37%
May 30 37.6 38.05
38.15
36.96
3.1M -2.62%
May 29 38.61 37.54
38.79
36.98
2.5M 3.71%
May 28 37.23 38.33
39.35
36.89
3.3M -2.92%
May 27 38.35 38.34
39.56
37.88
4.2M 1.19%
May 23 37.9 38
38.41
37.64
2.1M -2.29%
May 22 38.79 39.67
40.1
38.69
3.7M -3.15%
May 21 40.05 41.01
44.14
39.96
8.4M 0.15%
May 20 39.99 38.02
40.7
37.15
4.9M 5.40%
May 19 37.94 35.99
38.36
35.85
3.7M 4.14%
May 16 36.43 35.64
36.72
35.25
4.1M 3.29%
May 15 35.27 35.7
35.7
34.1
3.9M -1.32%
May 14 35.74 36.25
37.42
35.56
5.2M -1.27%
May 13 36.2 36.57
37.32
34.9
5.7M -0.47%
May 12 36.37 37.7
39.21
36.21
8.4M 0.28%
May 9 36.27 37.32
39.66
35.93
6.6M -0.68%
May 8 36.52 37.26
38.03
35.46
9.2M -0.54%
May 7 36.72 39.99
40
36.58
20.8M -21.45%
May 6 46.75 62.92
63.92
46.52
15.8M -26.56%
May 5 63.66 63.41
64.8
63.12
2.1M 0.24%
May 2 63.51 63.5
64.3
63.02
1.4M 1.16%
May 1 62.78 62.45
64
60.53
1.4M 0.61%
Apr 30 62.4 59.98
62.51
59.62
1.6M 2.55%
Apr 29 60.85 61.37
62.13
60.55
2.0M -1.07%
Apr 28 61.51 60.59
62.47
60.18
1.2M 1.77%
Apr 25 60.44 61.68
61.92
59.96
1.3M -2.14%
Apr 24 61.76 59.63
61.91
58.76
1.6M 3.82%
Apr 23 59.49 61.65
62.78
59.06
1.9M 0.30%
Apr 22 59.31 55.66
59.33
55.52
2.5M 7.39%
Apr 21 55.23 53.4
56.11
52.8
1.5M 2.68%
Apr 17 53.79 53.7
55.49
53.56
1.9M -0.28%
Apr 16 53.94 54.59
55.01
53.02
1.4M -0.88%
Apr 15 54.42 54.09
56.34
53.23
2.2M -0.38%
Apr 14 54.63 53.34
54.64
51.39
2.3M 7.05%
Apr 11 51.03 51.22
51.8
49.08
4.0M 1.43%
Apr 10 50.31 53.34
54.47
49.86
2.9M -9.6%
Apr 9 55.65 48.55
57.7
48.01
4.3M 12.88%
Apr 8 49.3 53.99
55.36
48.94
3.6M -5.92%
Apr 7 52.4 51.59
55.17
50.61
4.2M -3.73%
Apr 4 54.43 59.22
59.45
54.26
4.6M -7.13%
Apr 3 58.61 57.22
60.24
57.14
3.8M -6.18%
Apr 2 62.47 61.69
64.22
60.7
3.8M 0.90%
Apr 1 61.91 64.37
65.69
61.53
3.5M -2.99%
Mar 31 63.82 65.9
67.47
62.5
4.6M -9.36%
Mar 28 70.41 71.88
72.05
69.81
985K -1.95%
Mar 27 71.81 72.98
73.95
71.25
1.4M -1.47%
Mar 26 72.88 73.88
74.4
70.91
1.4M -0.99%
Mar 25 73.61 76.13
76.26
72.17
1.3M -3.56%
Mar 24 76.33 74.67
76.67
74.44
1.9M 0%